Related Experiment Video
Updated: Jan 25, 2026

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
Published on: September 25, 2018
An Update on Anti-CD137 Antibodies in Immunotherapies for Cancer
Dinh-Toi Chu1,2,3, Nguyen Duy Bac4, Khanh-Hoang Nguyen5
1Faculty of Biology, Hanoi National University of Education, Hanoi 100000, Vietnam. chudinhtoi.hnue@gmail.com.
Abstract:
The selective expression of CD137 on cells of the immune system (e.g., T and DC cells) and oncogenic cells in several types of cancer leads this molecule to be an attractive target to discover cancer immunotherapy. Therefore, specific antibodies against CD137 are being studied and developed aiming to activate and enhance anti-cancer immune responses as well as suppress oncogenic cells. Accumulating evidence suggests that anti-CD137 antibodies can be used separately to prevent tumor in some cases, while in other cases, these antibodies need to be co-administered with other antibodies or drugs/vaccines/regents for a better performance. Thus, in this work, we aim to update and discuss current knowledge about anti-cancer effects of anti-CD137 antibodies as mono- and combined-immunotherapies.
Insights
Anti-CD137 antibodies show promise in cancer immunotherapy. These antibodies can be used alone or in combination therapies to enhance anti-cancer immune responses and suppress tumor cells.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- CD137 is selectively expressed on immune cells like T cells and dendritic cells, as well as on cancer cells.
- This selective expression makes CD137 a promising target for developing novel cancer immunotherapies.
- Antibodies targeting CD137 are being investigated for their potential to modulate anti-cancer immune responses.
Purpose of the Study:
- To review and synthesize current research on the anti-cancer effects of anti-CD137 antibodies.
- To discuss the efficacy of anti-CD137 antibodies as monotherapies and in combination with other treatments.
- To provide an updated perspective on CD137-targeted cancer immunotherapy.
Main Methods:
- Literature review of preclinical and clinical studies on anti-CD137 antibodies.
- Analysis of data on the mechanisms of action for anti-CD137 antibodies.
- Synthesis of evidence regarding the use of anti-CD137 antibodies in various cancer types.
Main Results:
- Anti-CD137 antibodies can activate immune cells to enhance anti-tumor responses.
- Some cancers respond to anti-CD137 antibodies as monotherapy.
- Combination therapies involving anti-CD137 antibodies with other agents show improved efficacy in certain cases.
Conclusions:
- Anti-CD137 antibodies represent a significant advancement in cancer immunotherapy.
- The strategic use of anti-CD137 antibodies, both alone and in combination, holds potential for improved cancer treatment outcomes.
- Further research is warranted to optimize the application of CD137-targeted therapies.
Related Concept Videos
Tumor Immunotherapy
Antibody Structure
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibody Actions
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
Waterproofing and Anti-Bacterial Admixtures in Concrete
Waterproofing admixtures render concrete hydrophobic,...
Antibody Structure and Classes
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
Oxidation of Alkenes: Anti Dihydroxylation with Peroxy Acids

